Genetics of Parkinson's Disease: Mitochondrial Dysfunction Antibody Sampler Kit #30370
Product Information
Kit Usage Information
Protocols
- 5879: Western Blotting, Immunoprecipitation (Magnetic)
- 5933: Western Blotting, Immunoprecipitation (Magnetic), Immunofluorescence
- 6946: Western Blotting, Immunoprecipitation (Agarose)
- 7074: Western Blotting
- 13046: Western Blotting, Immunoprecipitation (Agarose)
- 32833: Western Blotting
- 51510: Western Blotting, Immunoprecipitation (Magnetic), Immunohistochemistry (Paraffin), Immunofluorescence, Immunofluorescence
- 81453: Western Blotting, Immunoprecipitation (Agarose)
Product Description
The Genetics of Parkinson's Disease: Mitochondrial Dysfunction Antibody Sampler Kit provides an economical means of investigating proteins implicated in mitochondrial dysfunction that are commonly mutated in Parkinson’s disease (PD) by western blot. The kit includes enough antibodies to perform two western blot experiments with each primary antibody.
Background
Parkinson’s disease (PD), the second most common neurodegenerative disease, is a progressive movement disorder characterized by rigidity, tremors, and postural instability. The pathological hallmark of PD is progressive loss of dopaminergic neurons in the substantia nigra of the ventral midbrain and the presence of intracellular Lewy bodies in surviving neurons of the brain stem (1). Mitochondrial dysfunction has been strongly implicated in the etiology of PD through both sporadic and familial cases. Several genes implicated in familial PD have been shown to play a role in mitochondrial dysfunction, including PRKN, PINK1, PARK7, PARK9, LRRK2, VPS35, and SNCA (2).
α-Synuclein (SNCA) aggregation in the substantia nigra is a pathological hallmark of PD. This aggregation has several downstream consequences, including direct interaction with mitochondria, disrupting mitochondrial metabolism (3).
Parkin (PRKN) is an E3 ubiquitin ligase responsible for ubiquitinating damaged or unneeded proteins for degradation by proteasomes. PTEN induced putative kinase 1 (PINK1) is a mitochondrial serine/threonine kinase that phosphorylates parkin, recruiting it to the mitochondria where both play a key role in maintaining mitochondrial health (4). Mutations in PINK1 and PRKN are the two most common causes of autosomal recessive early-onset PD (5).
DJ-1 (PARK7) is a multifunctional protein involved in protecting the cell against oxidative stress. DJ-1 is known to translocate to the mitochondria in response to oxidative stress, where it may play a protective role against mitochondrial dysfunction. Loss-of-function mutations in PARK7 have been linked to recessive early-onset PD (6,7). ATP13A2 (PARK9) is a lysosomal type 5 P-type ATPase associated with autosomal recessive early-onset PD, which functions in the autophagy-lysosomal pathway. Mutations in PARK9 have been shown to impair mitochondrial function and disrupt zinc homeostasis in PD (8,9).
Leucine-rich repeat kinase 2 (LRRK2) is a widely expressed multifunctional kinase with several cellular implications in PD. Mutations in the LRRK2 gene have an established link to both autosomal dominant and sporadic PD. These mutations lead to an abnormal elevation in kinase activity with downstream contributions to PD pathology, including dopaminergic neuronal cell death, oxidative damage, and α-synuclein accumulation (10,11). LRRK2 may play a role in mitochondrial homeostasis; thus, mutations in LRRK2 may increase the cell's susceptibility to reactive oxygen species (12).
Vacuolar protein sorting-associated protein 35 (VPS35) is a component of the retromer complex responsible for endosomal trafficking. It has been shown that deficits and mutations in VPS35 cause mitochondrial fragmentation and cell death in dopaminergic neurons (13,14). Mutations in the VPS35 gene have been linked to late-onset autosomal PD (15).
α-Synuclein (SNCA) aggregation in the substantia nigra is a pathological hallmark of PD. This aggregation has several downstream consequences, including direct interaction with mitochondria, disrupting mitochondrial metabolism (3).
Parkin (PRKN) is an E3 ubiquitin ligase responsible for ubiquitinating damaged or unneeded proteins for degradation by proteasomes. PTEN induced putative kinase 1 (PINK1) is a mitochondrial serine/threonine kinase that phosphorylates parkin, recruiting it to the mitochondria where both play a key role in maintaining mitochondrial health (4). Mutations in PINK1 and PRKN are the two most common causes of autosomal recessive early-onset PD (5).
DJ-1 (PARK7) is a multifunctional protein involved in protecting the cell against oxidative stress. DJ-1 is known to translocate to the mitochondria in response to oxidative stress, where it may play a protective role against mitochondrial dysfunction. Loss-of-function mutations in PARK7 have been linked to recessive early-onset PD (6,7). ATP13A2 (PARK9) is a lysosomal type 5 P-type ATPase associated with autosomal recessive early-onset PD, which functions in the autophagy-lysosomal pathway. Mutations in PARK9 have been shown to impair mitochondrial function and disrupt zinc homeostasis in PD (8,9).
Leucine-rich repeat kinase 2 (LRRK2) is a widely expressed multifunctional kinase with several cellular implications in PD. Mutations in the LRRK2 gene have an established link to both autosomal dominant and sporadic PD. These mutations lead to an abnormal elevation in kinase activity with downstream contributions to PD pathology, including dopaminergic neuronal cell death, oxidative damage, and α-synuclein accumulation (10,11). LRRK2 may play a role in mitochondrial homeostasis; thus, mutations in LRRK2 may increase the cell's susceptibility to reactive oxygen species (12).
Vacuolar protein sorting-associated protein 35 (VPS35) is a component of the retromer complex responsible for endosomal trafficking. It has been shown that deficits and mutations in VPS35 cause mitochondrial fragmentation and cell death in dopaminergic neurons (13,14). Mutations in the VPS35 gene have been linked to late-onset autosomal PD (15).
- Fahn, S. (2003) Ann N Y Acad Sci 991, 1-14.
- Henrich, M.T. et al. (2023) Mol Neurodegener 18, 83.
- Lurette, O. et al. (2023) Cell Death Dis 14, 729.
- Vizziello, M. et al. (2021) Cells 10, 3022. doi: 10.3390/cells10113022.
- Brooks, J. et al. (2009) J Med Genet 46, 375-81.
- Junn, E. et al. (2009) J Neurosci Res 87, 123-9.
- Canet-Avilés, R.M. et al. (2004) Proc Natl Acad Sci USA 101, 9103-8.
- Grünewald, A. et al. (2012) Neurobiol Aging 33, 1843.e1-7.
- Park, J.S. et al. (2014) Hum Mol Genet 23, 2802-15.
- Rui, Q. et al. (2018) Curr Neuropharmacol 16, 1348-1357.
- Jeong, G.R. and Lee, B.D. (2020) Cells 9, 2565. doi: 10.3390/cells9122565.
- Sanders, L.H. et al. (2014) Neurobiol Dis 62, 381-6.
- Tang, F.L. et al. (2015) Cell Rep 12, 1631-43.
- Wang, W. et al. (2016) Nat Med 22, 54-63.
- Williams, E.T. et al. (2017) J Parkinsons Dis 7, 219-233.
限制使用
除非 CST 的合法授书代表以书面形式书行明确同意,否书以下条款适用于 CST、其关书方或分书商提供的书品。 任何书充本条款或与本条款不同的客书条款和条件,除非书 CST 的合法授书代表以书面形式书独接受, 否书均被拒书,并且无效。
专品专有“专供研究使用”的专专或专似的专专声明, 且未专得美国食品和专品管理局或其他外国或国内专管机专专专任何用途的批准、准专或专可。客专不得将任何专品用于任何专断或治专目的, 或以任何不符合专专声明的方式使用专品。CST 专售或专可的专品提供专作专最专用专的客专,且专用于研专用途。将专品用于专断、专防或治专目的, 或专专售(专独或作专专成)或其他商专目的而专专专品,均需要 CST 的专独专可。客专:(a) 不得专独或与其他材料专合向任何第三方出售、专可、 出借、捐专或以其他方式专专或提供任何专品,或使用专品制造任何商专专品,(b) 不得复制、修改、逆向工程、反专专、 反专专专品或以其他方式专专专专专品的基专专专或技专,或使用专品开专任何与 CST 的专品或服专专争的专品或服专, (c) 不得更改或专除专品上的任何商专、商品名称、徽专、专利或版专声明或专专,(d) 只能根据 CST 的专品专售条款和任何适用文档使用专品, (e) 专遵守客专与专品一起使用的任何第三方专品或服专的任何专可、服专条款或专似专专
For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
XP is a registered trademark of Cell Signaling Technology, Inc.
All other trademarks are the property of their respective owners. Visit our
Trademark Information page.